Details of Host Protein-DME Interaction (HOSPPI)
| General Information of Drug-Metabolizing Enzyme (DME ID: DME0026) | |||||
|---|---|---|---|---|---|
| DME Name | Vitamin D(3) 25-hydroxylase (CYP27A1), Homo sapiens | DME Info | |||
| UniProt ID | |||||
| EC Number | EC: 1.14.15.15 (Click to Show/Hide the Complete EC Tree) | ||||
| Lineage | Species: Homo sapiens (Click to Show/Hide the Complete Species Lineage) | ||||
| Interactome | |||||
| Disease Specific Interactions between Host Protein and DME (HOSPPI) | |||||
|---|---|---|---|---|---|
| ICD Disease Classification 02 Neoplasms | |||||
| ICD-11: 2A00 Brain cancer | Click to Show/Hide the Full List of HOSPPI: 3 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Oligodendroglial tumour | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP27A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 2.14E-10; delta-beta: 6.84E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP27A1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Vitamin D(3) 25-hydroxylase. As a result, the interaction between DNMT and CYP27A1 can significantly affect the drug-metabolizing process of Vitamin D(3) 25-hydroxylase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Oligodendroglioma | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP27A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 6.68E-47; delta-beta: 7.00E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP27A1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Vitamin D(3) 25-hydroxylase. As a result, the interaction between DNMT and CYP27A1 can significantly affect the drug-metabolizing process of Vitamin D(3) 25-hydroxylase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Atypical teratoid/rhabdoid tumour | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP27A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 1.11E-16; delta-beta: 5.85E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP27A1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Vitamin D(3) 25-hydroxylase. As a result, the interaction between DNMT and CYP27A1 can significantly affect the drug-metabolizing process of Vitamin D(3) 25-hydroxylase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2B30 Lymphoma | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Lymphoma | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP27A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 3.06E-26; delta-beta: 7.09E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP27A1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Vitamin D(3) 25-hydroxylase. As a result, the interaction between DNMT and CYP27A1 can significantly affect the drug-metabolizing process of Vitamin D(3) 25-hydroxylase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2B60 Squamous cell carcinoma | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Squamous cell carcinoma | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP27A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Adjacent Tissue | Significant hypermethylation p-value: 4.46E-03; delta-beta: 3.44E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP27A1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Vitamin D(3) 25-hydroxylase. As a result, the interaction between DNMT and CYP27A1 can significantly affect the drug-metabolizing process of Vitamin D(3) 25-hydroxylase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue adjacent to the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2C12 Liver cancer | Click to Show/Hide the Full List of HOSPPI: 2 HOSPPI | ||||
| Transcription-factor regulation | |||||
| Transcription factor Sp1 (SP1) | Liver cancer | Activation | |||
| Uniprot ID | |||||
| Interaction Name | SP1-CYP27A1 interaction | [1] | |||
| Studied Cell Lines | HepG2 cell line | ||||
| Ensembl ID | |||||
| Description | Transcription factor Sp1 (SP1) is reported to activate the transcription of CYP27A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Vitamin D(3) 25-hydroxylase. As a result, the interaction between SP1 and CYP27A1 can activate the drug-metabolizing process of Vitamin D(3) 25-hydroxylase. | ||||
| Transcription factor Sp3 (SP3) | Liver cancer | Activation | |||
| Uniprot ID | |||||
| Interaction Name | SP3-CYP27A1 interaction | [1] | |||
| Studied Cell Lines | HepG2 cell line | ||||
| Ensembl ID | |||||
| Description | Transcription factor Sp3 (SP3) is reported to activate the transcription of CYP27A1 gene, which leads to an increased expression of the drug-metabolizing enzyme Vitamin D(3) 25-hydroxylase. As a result, the interaction between SP3 and CYP27A1 can activate the drug-metabolizing process of Vitamin D(3) 25-hydroxylase. | ||||
| ICD-11: 2C82 Prostate cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Prostate cancer | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP27A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 1.38E-44; delta-beta: 6.18E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP27A1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Vitamin D(3) 25-hydroxylase. As a result, the interaction between DNMT and CYP27A1 can significantly affect the drug-metabolizing process of Vitamin D(3) 25-hydroxylase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2C90 Renal cell carcinoma | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Renal cell carcinoma | Moderate hypermethylation | |||
| Interaction Name | DNMT-CYP27A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Other Disease Section | Moderate hypermethylation p-value: 4.12E-02; delta-beta: 2.04E-02 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hyper-methylate the CYP27A1 gene, which leads to a moderatly decreased expression of the drug-metabolizing enzyme Vitamin D(3) 25-hydroxylase. As a result, the interaction between DNMT and CYP27A1 can moderatly affect the drug-metabolizing process of Vitamin D(3) 25-hydroxylase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
DME methylation in tissue other than the diseased tissue of patients
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2E06 Prostate cancer metastasis | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Prostate cancer metastasis | Significant hypermethylation | |||
| Interaction Name | DNMT-CYP27A1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 2.20E-07; delta-beta: 8.31E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP27A1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Vitamin D(3) 25-hydroxylase. As a result, the interaction between DNMT and CYP27A1 can significantly affect the drug-metabolizing process of Vitamin D(3) 25-hydroxylase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| References | |||||
|---|---|---|---|---|---|
| 1 | Functional analysis of the promoter of human sterol 27-hydroxylase gene in HepG2 cells. Gene. 2002 Jan 23;283(1-2):133-43. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.